ITOS iTeos Therapeutics, Inc. Insider Trading

CEO Michel Detheux sold 104.6K shares for $1.0M (blended avg $10.02) on Jun 9–10, reducing stake by 52.7%

Detheux executed 4 separate sales totaling 104,565 shares for $1,048,264.12 at an average price of $10.02, cutting his holding from 198,592 shares to 94,027 shares—a 52.7% reduction. The timing is notable: the stock was trading at $10.00 on the filing date, approximately 44.4% below its 52-week high of $17.97, and had rallied 44.5% over the prior 30 days. Detheux's prior trades at ITOS (5 recent sales from June 4–6) do not yet have measurable 30-day or 90-day outcomes, so comparison to his same-ticker history is not yet possible. The underlying company is unprofitable with a net loss of $34,613,000 in the latest full year, though it reported annual revenue growth of 177.9%, positioning this transaction amid a financially volatile period for the firm.

iTeos director David Hallal exits entire position with 3 sales of 114.7K shares totaling $1.2M at blended $10.15 average.

Director Hallal David completed a full liquidation of his 114,682 shares at iTeos across three consecutive trading days (June 4–6, 2025), with transaction prices ranging from $10.07 to $10.24 and a blended average of $10.15. The complete sale of his entire stake is notable given that iTeos is unprofitable with net income of $-34,613,000 and generated zero revenue in the latest quarter, though the company did report annual revenue growth of +177.9% year-over-year. The stock has recovered significantly in the short term (+57.9% over 30 days, +44.3% over 90 days) but remains -43.4% below its 52-week high of $17.97, and is trading at $10.17 at the time of filing, essentially at the exit prices. The total elimination of the director's holding signals a meaningful change in his ownership position and warrants investor attention given the company's pre-revenue clinical-stage profile.

CEO Detheux Michel sells entire 156,847-share stake in ITOS for $1.6M across 6 transactions (Jun 4–6)

Michel, iTeos' Chief Executive Officer, executed 6 separate sales totaling 156,847 shares for $1,592,519.82 between June 4–6, 2025, at prices ranging from $10.10 to $10.21 (blended average $10.15), eliminating his entire shareholding from 156,847 shares to zero. The company is unprofitable with net income of $-34,613,000.00 and latest-quarter revenue of $0.00, despite posting annual revenue growth of +177.9%, suggesting the firm is in a pre-commercial or early-stage therapeutic development phase. The stock's 52-week range of $5.04–$17.97 indicates volatility; the current price of $10.17 sits -43.4% from the 52-week high and +57.9% above its 30-day level, placing the sale near recent strength but well below peak valuations. A CEO's complete exit from equity ownership at a biotech with negative earnings and minimal revenue raises material questions about leadership confidence or personal liquidity needs, especially given the absence of any offsetting purchases or indication of scheduled plan activity.

EcoR1 Capital acquires 4,958,978 shares ($38.7M) in 2 tranches; post-transaction stake rises to 10.69M shares.

EcoR1 Capital, a 10% owner, executed two separate purchases totaling 4,958,978 shares for $38,685,561.58 at a blended average price of $7.80 per share on May 14–15, 2025. The combined acquisition increased the fund's holdings by 86.5% from 5,730,000 to 10,688,978 shares, deepening its stake in a pre-revenue, unprofitable biotech company. Despite the significant capital deployment and enlarged position, the current stock price of $7.81 remains 56.8% below the 52-week high of $18.09, and the insider's cross-ticker track record shows minimal prior trading activity—17 prior buys with an average 30-day return of −0.3%, providing limited direct precedent for assessing the quality of this buying decision at iTeos. The transaction warrants investor attention given the scale of capital commitment and the company's early-stage revenue profile.

Venture fund MPM Bioventures sold 630,191 ITOS shares at $8.06 on 5/13, reducing stake by 23.0% to 2.11M shares.

MPM Bioventures, a major shareholder holding 2.74M shares pre-transaction, sold 630,191 shares (630.2K shares) at $8.06, reducing its stake to 2.11M shares (-23.0%). The sale occurred at a price that is -55.9% below the 52-week high of $18.09, while the stock is up +34.3% over the prior 30 days and +7.7% over 90 days. iTeos Therapeutics remains unprofitable with net income of $-34.6M on quarterly revenue of $0.00, though annual revenue growth was +177.9%. The substantial 23% reduction in holdings by this institutional investor coincides with deteriorating valuation metrics (well below 52-week highs) and the company's persistent loss-making status, despite recent price momentum.

Chief insider Gadicke sold 1,031,931 shares of ITOS at $8.06; stock down 55.9% from 52-week high, company unprofitable.

GADICKE ANSBERT sold 1,031,931 shares at $8.06, reducing holdings by 23.0% from 4,484,728 to 3,452,797 shares. The timing is notable given the stock's substantial decline: ITOS trades at $7.97 versus a 52-week high of $18.09 (down 55.9%), though it has recovered 34.3% over the past 30 days. The company's fundamentals remain challenged—it is unprofitable with net income of $-34,613,000 and zero latest-quarter revenue, despite posting 177.9% annual revenue growth. A material reduction in senior insider holdings at a depressed valuation warrants investor scrutiny of the company's runway and near-term catalysts, particularly given the unprofitable operating status and the timing of this large stake reduction.

MPM BioVentures sold 630,191 shares of ITOS at $8.06; still holds 2,108,594 shares post-transaction

MPM BioVentures 2014, L.P. sold 630,191 shares (23.0% reduction in holdings) at $8.06 on 2025-05-13, divesting $5,079,339.46 while retaining 2,108,594 shares. The sale occurred against a backdrop of substantial volatility: the stock has declined 55.9% from its 52-week high of $18.09 but posted a 34.3% gain over the prior 30 days. ITOS is pre-revenue (latest quarter revenue $0.00) with a full-year net loss of $-34,613,000.00, though revenue grew 177.9% year-over-year. The partial reduction in a major institutional holder's stake, while maintaining material exposure (2.11M shares remain), warrants monitoring as the company scales toward profitability and market validation.

CFO Gall Matthew buys 5,000 ITOS shares at $7.73 amid -54.9% 90-day decline; stock down -56.3% from 52-week high.

CFO Matthew Gall purchased 5,000 shares of iTeos Therapeutics at $7.73, raising his holdings from 60,429 to 65,429 shares, in a context of severe recent price deterioration: the stock has declined 54.9% over 90 days and is -56.3% below its 52-week high of $18.09. The company is unprofitable with net income of $-45,358,000 and quarterly revenue of $0.00, alongside a -95.3% decline in annual revenue growth. Gall's cross-ticker insider buy track record shows 1 prior purchase with a 100.00% 90-day win rate and +29.8% average 90d return; at ITOS specifically, his single prior buy on 2023-10-12 did produce a +29.8% 90-day return and was well-timed. This buy occurs in a substantially depressed price environment relative to both recent history and the insider's own demonstrated timing patterns elsewhere, yet the company's operational deterioration and cash burn constraints warrant scrutiny of its trajectory.